Kura Oncology (NASDAQ:KURA) Insider Brian Powl Sells 4,345 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Brian Powl sold 4,345 shares of Kura Oncology stock in a transaction on Friday, August 21st. The shares were sold at an average price of $11.89, for a total transaction of $51,662.05. Following the completion of the sale, the insider directly owned 169,269 shares of the company’s stock, valued at approximately $2,012,608.41. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kura Oncology Price Performance

KURA stock opened at $12.40 on Tuesday. The stock has a market capitalization of $1.10 billion, a PE ratio of -3.68 and a beta of 0.38. The company’s 50-day moving average is $10.59 and its 200-day moving average is $9.50. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. Kura Oncology, Inc. has a 1 year low of $7.36 and a 1 year high of $12.90.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The company had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. Equities research analysts expect that Kura Oncology, Inc. will post -3.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KURA has been the subject of several recent research reports. Jefferies Financial Group set a $24.00 price objective on Kura Oncology in a report on Thursday, May 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Friday, July 17th. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research note on Thursday, June 4th. CLSA set a $24.00 price objective on shares of Kura Oncology in a report on Thursday, June 4th. Finally, Wall Street Zen upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently modified their holdings of KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Kura Oncology by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after purchasing an additional 2,977 shares during the last quarter. Strs Ohio purchased a new stake in shares of Kura Oncology during the 1st quarter valued at $143,000. Legal & General Group Plc raised its stake in shares of Kura Oncology by 35.1% during the 2nd quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock worth $421,000 after purchasing an additional 18,930 shares during the period. Rhumbline Advisers raised its stake in shares of Kura Oncology by 13.0% during the 2nd quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock worth $686,000 after purchasing an additional 13,690 shares during the period. Finally, American Century Companies Inc. boosted its holdings in shares of Kura Oncology by 244.5% in the 2nd quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock worth $1,343,000 after buying an additional 165,189 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.